>沙特阿拉伯、土耳其和埃及 HbA1c 检测市场，按产品类型（仪器、试剂和消耗品）、检测方式（处方检测和 OTC 检测）、技术（离子交换 HPCL、酶促测定、亲和结合色谱法、浊度抑制免疫测定法等）、最终用户（实验室、医院、诊所、家庭护理、门诊中心、药房/药店等）、分销渠道（第三方分销、直销和零售）划分 - 行业趋势和预测到 2030 年。
沙特阿拉伯、土耳其和埃及糖化血红蛋白检测市场分析与洞察
人们对糖尿病和肾脏疾病的认识不断提高，这增强了市场的需求。为获得更好的医疗服务而增加的医疗支出也促进了市场的增长。在这一关键时期，主要的市场参与者专注于各种服务的推出和批准。此外，糖尿病护理点设备的改进也促进了对糖尿病或 HBA1C 检测的需求上升。
Data Bridge Market Research 分析称，在 2023 年至 2030 年的预测期内，HbA1c 检测市场预计将以 4.4% 的复合年增长率增长，预计到 2030 年沙特阿拉伯的市场规模将达到 6159 万美元；在 2023 年至 2030 年的预测期内，土耳其的 HbA1c 检测市场预计将以 5.4% 的复合年增长率增长，预计到 2030 年土耳其的市场规模将达到 7373 万美元；在 2023 年至 2030 年的预测期内，埃及的 HbA1c 检测市场预计将以 5.4% 的复合年增长率增长，预计到 2030 年埃及的市场规模将达到 6594 万美元。随着先进技术的发展，仪器部门预计将推动市场增长
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021 (可定制为 2015-2020) |
|
定量单位 |
收入（百万美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
按产品类型（仪器、试剂和耗材）、检测方式（处方检测和 OTC 检测）、技术（离子交换 HPCL、酶促测定、亲和结合色谱、浊度抑制免疫测定等）、最终用户（实验室、医院、诊所、家庭护理、流动中心、药房/药店等）、分销渠道（第三方分销、直销和零售）、国家（沙特阿拉伯、埃及和土耳其） |
|
覆盖国家 |
沙特阿拉伯、埃及和土耳其 |
|
涵盖的市场参与者 |
沙特阿拉伯、埃及和土耳其 HbA1c 检测市场的一些主要参与者包括西门子医疗有限公司、A. Menarini Diagnostics srl、ARKRAY, Inc.、Trinity Biotech、赛默飞世尔科技公司、雅培、万孚生物、F. Hoffmann-La Roche Ltd、Ortho Clinical Diagnostics、DxGen Corp. 等。 |
沙特阿拉伯、土耳其和埃及 HbA1c 检测市场定义
血液检查称为糖化血红蛋白 (HbA1C) 测试，可显示您过去两到三个月的平均血糖 (葡萄糖) 水平。您的血液中含有葡萄糖；葡萄糖是从您吃的食物中获取的一种糖。葡萄糖为您的细胞提供能量。激素胰岛素有助于细胞吸收葡萄糖。如果您患有糖尿病，您的身体要么产生不足的胰岛素，要么您的细胞无法正确利用它。由于葡萄糖无法进入您的细胞，您的血糖水平会升高。
糖尿病是一种全球性流行病，在发展中国家和发达国家的患病率都在迅速上升。糖化血红蛋白 (HbA1c) 可以替代空腹血糖来诊断糖尿病，HbA1c 是长期血糖控制的重要指标，能够反映前两到三个月的累积血糖史。HbA1c 可以可靠地测量慢性高血糖，并且与长期糖尿病并发症的风险密切相关。无论是否患有糖尿病，升高的 HbA1c 也被认为是冠心病和中风的独立风险因素。单次 HbA1c 测试提供的宝贵信息使其成为诊断和预后的糖尿病的可靠生物标志物。但是，HBA1C 检测设备和试剂盒的高成本以及产品审批和商业化的标准预计将抑制市场增长。
沙特阿拉伯、土耳其和埃及糖化血红蛋白检测市场动态
本节旨在了解市场驱动因素、优势、机遇、限制和挑战。下面将详细讨论所有这些内容：
驱动程序
- 全球糖尿病患病率不断上升
未来 20 岁以下的糖尿病患者人数可能会更快增加。还有各种研究显示 2 型糖尿病患者人数增加，包括儿童肥胖症的患病率增加。育龄人群患糖尿病可能非常重要，因为母亲患糖尿病会增加儿童患糖尿病的风险。
对更准确、时间限制更少的 hba1c 检测的需求不断增长，这促使主要参与者采取战略举措。因为糖尿病患者患心脏病或中风、糖尿病并发症和过早死亡的风险高于非糖尿病患者
- 人们越来越意识到血糖控制的重要性
血糖控制不佳的特点是血糖和糖化血红蛋白长期处于高水平，例如糖尿病患者，尤其是接受胰岛素治疗的患者，有发生低血糖的风险。一些研究表明，增加非运动性体力活动可有效降低餐后高血糖并改善血糖控制
多项研究表明，许多糖尿病患者的血糖控制水平不足且较差。这与年龄较大、糖尿病持续时间较长、胰岛素治疗、饮食依从性差以及未能设定控制目标有关。这需要关注已确定的因素和量身定制的管理机制，以保持良好的血糖控制。因此，人们越来越关注这个因素，并准备控制自己的血糖水平
然而，糖尿病知识水平低可以预测血糖控制不佳，但不能预测药物依从性。
克制
- Hba1c 检测设备和试剂盒价格昂贵
设备和试剂盒的成本在 hba1c 检测市场中起着重要作用。因为这些设备和试剂盒的开发过程非常昂贵，需要很长时间才能通过研发、监管和其他各种合规性。这些设备和试剂盒需要从设计到生产再到产品制造方式的流程有很高的理解，因为任何阶段的单个错误都可能导致整个生产中断。
例如，
- 2020 年 12 月，根据 NCBI 的文章，在沙特阿拉伯，糖尿病患者的医疗费用与非糖尿病患者的医疗费用相比高出十倍
然而，这些 hba1c 设备和套件需要有效的投资才能成功运行，同时还需要项目风险管理计划。
机会
-
新兴市场中hba1c检测的采用率不断提高
法规和医生建议在提高 hba1c 检测的采用率方面发挥着重要作用。严格的规则和法规对于政府批准以确保人类和环境的安全是必不可少的。由于 hba1c 是诊断前驱糖尿病和糖尿病的常用测试之一，也被认为是帮助您和您的医疗团队管理糖尿病的主要测试。医生还建议前驱糖尿病患者或患有边缘性糖尿病的人接受测试以检查他们的血糖水平是否稳定。一般医生认为，患有糖尿病和前驱糖尿病的人应该每 3 个月检测一次 HbA1c。
挑战
- 贫血或肾病患者糖化血红蛋白 (hba1c)结果解读面临的挑战
在慢性肾病环境中，与 HbA1c 预测能力相关的潜在挑战仍然存在。血液中的多余液体和废物会留在体内，并可能导致心脏病和中风等其他健康问题。
然而，慢性肾病患者的 HbA1c 水平可能会假性升高或降低，因为尿毒症环境会缩短红细胞寿命。多项研究推测，在炎症和营养不良患病率较高的人群中，如慢性肾病患者，HbA1c 水平对临床结果的预测能力可能较低。
例如-
- 2022 年 2 月 – 根据 ncbi 文章，海湾合作委员会国家的研究人员进行的研究表明，对于晚期慢性肾病糖尿病患者来说，7% 至 8% 的 HbA1c 水平可能是获得最佳结果的最佳水平
然而，轻度至中度贫血和慢性肾脏病可能不会影响糖化血红蛋白和血糖水平之间的关系。
最新动态
- 2020 年 3 月，PTS Diagnostics 最近宣布将推出用于 A1CNow®+ 测试系统的 A1CNow+ 对照品。A1CNow+ 对照品最初可在美国、欧盟和英国购买。它们可冷冻保存长达三年，冷藏保存八个月，或在室温下保存七天。该溶液有两个级别，每个级别都装在滴管式小瓶中，可在几分钟内有效使用。其目标是确保准确的 A1C 结果。
- 2023 年 3 月，雅培宣布与心血管系统公司 (CSI) 达成最终协议，后者是一家医疗设备制造商，拥有用于治疗外周和冠状动脉疾病的尖端动脉粥样硬化切除系统，根据该协议，雅培将收购 CSI。雅培市场领先的血管设备产品线将通过收购 CSI 获得新的互补创新。这为公司带来了业务增长。
沙特阿拉伯、土耳其和埃及 HbA1c 检测市场范围
沙特阿拉伯、土耳其和埃及的 HbA1c 检测市场分为五个显著的细分市场，例如产品类型、检测模式、技术、最终用户和分销渠道。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
按产品类型
- 仪器
- 试剂和耗材
根据产品类型，沙特阿拉伯、土耳其和埃及的 HbA1c 检测市场分为仪器、试剂和消耗品。
按测试方式
- 基于处方的测试
- OTC测试
根据检测模式，沙特阿拉伯、土耳其和埃及的 HbA1c 检测市场分为处方检测和 OTC 检测。
按技术分类
- 免疫抑制比浊法
- 离子交换色谱柱
- 亲和层析
- 酶促分析
- 其他的
根据技术，沙特阿拉伯、土耳其和埃及的 HbA1c 检测市场分为离子交换 HPCL、酶促测定、亲和结合色谱法、浊度抑制免疫测定法等。
由最终用户
- 实验室
- 医院
- 诊所
- 家庭护理
- 流动中心
- 药房/药店
- 其他的
根据最终用户，沙特阿拉伯、土耳其和埃及的 HbA1c 检测市场分为实验室、医院、诊所、家庭护理、门诊中心、药房/药店和其他。
按分销渠道
- 直销
- 第三方分销
- 零售销售
根据分销渠道，沙特阿拉伯、土耳其和埃及的 HbA1c 检测市场分为第三方分销、直销和零售。
沙特阿拉伯、土耳其和埃及 HbA1c 检测市场区域分析/见解
沙特阿拉伯、土耳其和埃及的 HbA1c 检测市场分为四个显著的部分，即产品类型、检测模式、技术、最终用户和分销渠道。
本市场报告涵盖的国家包括沙特阿拉伯、土耳其和埃及。由于人口中糖尿病和糖尿病前期患病率不断上升，土耳其预计将主导沙特阿拉伯、土耳其和埃及的 HbA1c 检测市场。
报告的州部分还提供了影响各个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测各个国家市场情景的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了欧洲品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战，以及销售渠道的影响。
竞争格局和沙特阿拉伯、土耳其和埃及 HbA1c 检测市场份额分析
沙特阿拉伯、土耳其和埃及 HbA1c 检测市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品批准、产品宽度和广度、应用主导地位和技术生命线曲线。以上提供的数据点仅与公司对沙特阿拉伯、土耳其和埃及 HbA1c 检测市场的关注有关。
沙特阿拉伯、土耳其和埃及 HbA1c 检测市场的一些主要参与者包括西门子医疗有限公司、A. Menarini Diagnostics srl、ARKRAY, Inc.、Trinity Biotech、赛默飞世尔科技公司、雅培、万孚生物、F. Hoffmann-La Roche Ltd、Ortho Clinical Diagnostics、DxGen Corp. 等。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE SAUDI ARABIA, TURKEY, AND EGYPT HBA1C TESTING MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 SAUDI ARABIA, TURKEY, AND EGYPT HBA1C TESTING MARKET, INDUSTRY INSIGHTS
6 REGULATORY FRAMEWORK
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING PREVALENCE OF DIABETES WORLDWIDE
7.1.2 GROWING AWARENESS ABOUT THE IMPORTANCE OF GLYCEMIC CONTROL
7.1.3 GROWING DEMAND FOR POINT-OF-CARE TESTING DEVICES
7.2 RESTRAINTS
7.2.1 HIGH COST OF HBA1C TESTING DEVICES AND KITS
7.2.2 INADEQUATE HEALTHCARE INFRASTRUCTURE IN DEVELOPING COUNTRIES
7.3 OPPORTUNITIES
7.3.1 INCREASING ADOPTION OF HBA1C TESTING IN EMERGING MARKETS
7.3.2 INTEGRATION OF HBA1C TESTING WITH ELECTRONIC MEDICAL RECORDS AND TELEMEDICINE
7.4 CHALLENGES
7.4.1 INACCURATE RESULTS DUE TO INTERFERENCE FROM VARIOUS HEMOGLOBIN VARIANTS
7.4.2 CHALLENGES IN INTERPRETING HBA1C RESULTS IN PATIENTS WITH ANEMIA OR KIDNEY DISEASE
8 SAUDI ARABIA, TURKEY, AND EGYPT HBA1C TESTING MARKET, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 INSTRUMENTS
8.2.1 POINT OF CARE DEVICES
8.2.2 FACILITY BASED PLATFORM
8.3 REAGENTS AND CONSUMABLES
9 SAUDI ARABIA, TURKEY, AND EGYPT HBA1C TESTING MARKET, BY MODE OF TESTING
9.1 OVERVIEW
9.2 PRESCRIPTION BASED TESTING
9.3 OTC TESTING
10 SAUDI ARABIA, TURKEY, AND EGYPT HBA1C TESTING MARKET, BY TECHNOLOGY
10.1 OVERVIEW
10.2 TURBIDIMETRIC INHIBITION IMMUNOASSAY
10.3 ION-EXCHANGE HPLC
10.4 AFFINITY BINDING CHROMATOGRAPHY
10.5 ENZYMATIC ASSAY
10.6 OTHERS
11 SAUDI ARABIA, TURKEY, AND EGYPT HBA1C TESTING MARKET, BY END USER
11.1 OVERVIEW
11.2 LABORATORIES
11.3 HOSPITALS
11.4 CLINICS
11.5 HOMECARE
11.6 AMBULATORY CENTRES
11.7 PHARMACIES/ DRUG STORES
11.8 OTHERS
12 SAUDI ARABIA, TURKEY, AND EGYPT HBA1C TESTING MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT SALES
12.3 THIRD PARTY DISTRIBUTION
12.4 RETAIL SALES
12.4.1 HOSPITAL PHARMACY
12.4.2 ONLINE PHARMACY
12.4.3 OTHERS
13 SAUDI ARABIA, TURKEY AND EGYPT HBA1C TESTING MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: SAUDI ARABIA
13.2 COMPANY SHARE ANALYSIS: TURKEY
13.3 COMPANY SHARE ANALYSIS: EGYPT
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 F.HOFFMANN- LA ROCHE LTD.
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 PRODUCT PORTFOLIO
15.1.4 RECENT DEVELOPMENTS
15.2 SIEMENS HEALTHINEERS AG
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 PRODUCT PORTFOLIO
15.2.4 RECENT DEVELOPMENTS
15.3 ORTHO CLINICAL DIAGNOSTICS
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENTS
15.4 ARKRAY, INC.
15.4.1 COMPANY SNAPSHOT
15.4.2 PRODUCT PORTFOLIO
15.4.3 RECENT DEVELOPMENTS
15.5 THERMO FISCHER SCIENTIFIC INC.
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPMENTS
15.6 ABBOTT
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENT
15.7 BIO RAD LABORATORIES, INC.
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENT
15.8 DIASYS DIAGNOSTIC SYSTEMS GMBH
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENTS
15.9 DXGEN CORP.
15.9.1 COMPANY SNAPSHOT
15.9.2 PRODUCT PORTFOLIO
15.9.3 RECENT DEVELOPMENTS
15.1 A. MENARINNI DIAGNOSTICS S.R.L
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENTS
15.11 PTS DIAGNOSTICS
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENT
15.12 RADIOMETER MEDICAL APS
15.12.1 COMPANY SNAPSHOT
15.12.2 PRODUCT PORTFOLIO
15.12.3 RECENT DEVELOPMENTS
15.13 TRINITY BIOTECH
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENTS
15.14 VITROSENS BIOTECHNOLOGY
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENTS
15.15 WONDFO
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENTS
16 QUESTIONNAIRE
17 RELATED REPORTS
图片列表
FIGURE 1 SAUDI ARABIA, TURKEY, AND EGYPT HBA1C TESTING MARKET: SEGMENTATION
FIGURE 2 SAUDI ARABIA, TURKEY, AND EGYPT HBA1C TESTING MARKET: DATA TRIANGULATION
FIGURE 3 SAUDI ARABIA, TURKEY, AND EGYPT HBA1C TESTING MARKET: DROC ANALYSIS
FIGURE 4 SAUDI ARABIA, TURKEY, AND EGYPT HBA1C TESTING MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 SAUDI ARABIA, TURKEY, AND EGYPT HBA1C TESTING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 SAUDI ARABIA, TURKEY, AND EGYPT HBA1C TESTING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 SAUDI ARABIA, TURKEY, AND EGYPT HBA1C TESTING MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 SAUDI ARABIA, TURKEY, AND EGYPT HBA1C TESTING MARKET: DBMR MARKET POSITION GRID
FIGURE 9 SAUDI ARABIA, TURKEY, AND EGYPT HBA1C TESTING MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 SAUDI ARABIA, TURKEY, AND EGYPT HBA1C TESTING MARKET: SEGMENTATION
FIGURE 11 GROWING AWARENESS OF DIABETES AND INCREASING HEALTHCARE EXPENDITURE IS EXPECTED TO DRIVE THE GROWTH OF THE SAUDI ARABIA HBA1C TESTING MARKET FROM 2023 TO 2030
FIGURE 12 GROWING AWARENESS OF DIABETES AND INCREASING HEALTHCARE EXPENDITURE IS EXPECTED TO DRIVE THE GROWTH OF THE TURKEY HBA1C TESTING MARKET FROM 2023 TO 2030
FIGURE 13 GROWING AWARENESS OF DIABETES AND INCREASING HEALTHCARE EXPENDITURE IS EXPECTED TO DRIVE THE GROWTH OF THE EGYPT HBA1C TESTING MARKET FROM 2023 TO 2030
FIGURE 14 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE SAUDI ARABIA HBA1C TESTING MARKET IN 2023 & 2030
FIGURE 15 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE TURKEY HBA1C TESTING MARKET IN 2023 & 2030
FIGURE 16 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EGYPT HBA1C TESTING MARKET IN 2023 & 2030
FIGURE 17 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF SAUDI ARABIA, TURKEY & EGYPT HBA1C TESTING MARKET
FIGURE 18 SAUDI ARABIA HBA1C TESTING MARKET: BY PRODUCT TYPE, 2022
FIGURE 19 SAUDI ARABIA HBA1C TESTING MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 20 SAUDI ARABIA HBA1C TESTING MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 21 SAUDI ARABIA HBA1C TESTING MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 22 TURKEY HBA1C TESTING MARKET: BY PRODUCT TYPE, 2022
FIGURE 23 TURKEY HBA1C TESTING MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 24 TURKEY HBA1C TESTING MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 25 TURKEY HBA1C TESTING MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 26 EGYPT HBA1C TESTING MARKET: BY PRODUCT TYPE, 2022
FIGURE 27 EGYPT HBA1C TESTING MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 28 EGYPT HBA1C TESTING MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 29 EGYPT HBA1C TESTING MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 30 SAUDI ARABIA HBA1C TESTING MARKET: BY MODE OF TESTING, 2022
FIGURE 31 SAUDI ARABIA HBA1C TESTING MARKET: BY MODE OF TESTING, 2023-2030 (USD MILLION)
FIGURE 32 SAUDI ARABIA HBA1C TESTING MARKET: BY MODE OF TESTING, CAGR (2023-2030)
FIGURE 33 SAUDI ARABIA HBA1C TESTING MARKET: BY MODE OF TESTING, LIFELINE CURVE
FIGURE 34 TURKEY HBA1C TESTING MARKET: BY MODE OF TESTING, 2022
FIGURE 35 TURKEY HBA1C TESTING MARKET: BY MODE OF TESTING, 2023-2030 (USD MILLION)
FIGURE 36 TURKEY HBA1C TESTING MARKET: BY MODE OF TESTING, CAGR (2023-2030)
FIGURE 37 TURKEY HBA1C TESTING MARKET: BY MODE OF TESTING, LIFELINE CURVE
FIGURE 38 EGYPT HBA1C TESTING MARKET: BY MODE OF TESTING, 2022
FIGURE 39 EGYPT HBA1C TESTING MARKET: BY MODE OF TESTING, 2023-2030 (USD MILLION)
FIGURE 40 EGYPT HBA1C TESTING MARKET: BY MODE OF TESTING, CAGR (2023-2030)
FIGURE 41 EGYPT HBA1C TESTING MARKET: BY MODE OF TESTING, LIFELINE CURVE
FIGURE 42 SAUDI ARABIA HBA1C TESTING MARKET: BY TECHNOLOGY, 2022
FIGURE 43 SAUDI ARABIA HBA1C TESTING MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 44 SAUDI ARABIA HBA1C TESTING MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 45 SAUDI ARABIA HBA1C TESTING MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 46 TURKEY HBA1C TESTING MARKET: BY TECHNOLOGY, 2022
FIGURE 47 TURKEY HBA1C TESTING MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 48 TURKEY HBA1C TESTING MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 49 TURKEY HBA1C TESTING MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 50 EGYPT HBA1C TESTING MARKET: BY TECHNOLOGY, 2022
FIGURE 51 EGYPT HBA1C TESTING MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 52 EGYPT HBA1C TESTING MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 53 EGYPT HBA1C TESTING MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 54 SAUDI ARABIA HBA1C TESTING MARKET: BY END USER, 2022
FIGURE 55 SAUDI ARABIA HBA1C TESTING MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 56 SAUDI ARABIA HBA1C TESTING MARKET: BY END USER, CAGR (2023-2030)
FIGURE 57 SAUDI ARABIA HBA1C TESTING MARKET: BY END USER, LIFELINE CURVE
FIGURE 58 TURKEY HBA1C TESTING MARKET: BY END USER, 2022
FIGURE 59 TURKEY HBA1C TESTING MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 60 TURKEY HBA1C TESTING MARKET: BY END USER, CAGR (2023-2030)
FIGURE 61 TURKEY HBA1C TESTING MARKET: BY END USER, LIFELINE CURVE
FIGURE 62 EGYPT HBA1C TESTING MARKET: BY END USER, 2022
FIGURE 63 EGYPT HBA1C TESTING MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 64 EGYPT HBA1C TESTING MARKET: BY END USER, CAGR (2023-2030)
FIGURE 65 EGYPT HBA1C TESTING MARKET: BY END USER, LIFELINE CURVE
FIGURE 66 SAUDI ARABIA HBA1C TESTING MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 67 SAUDI ARABIA HBA1C TESTING MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 68 SAUDI ARABIA HBA1C TESTING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 69 SAUDI ARABIA HBA1C TESTING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 70 TURKEY HBA1C TESTING MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 71 TURKEY HBA1C TESTING MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 72 TURKEY HBA1C TESTING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 73 TURKEY HBA1C TESTING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 74 EGYPT HBA1C TESTING MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 75 EGYPT HBA1C TESTING MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 76 EGYPT HBA1C TESTING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 77 EGYPT HBA1C TESTING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 78 SAUDI ARABIA HBA1C TESTING MARKET: COMPANY SHARE 2022 (%)
FIGURE 79 TURKEY HBA1C TESTING MARKET: COMPANY SHARE 2022 (%)
FIGURE 80 EGYPT HBA1C TESTING MARKET: COMPANY SHARE 2022 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
